The lecture highlights the rising prevalence of fatty liver disease in obesity and diabetes, emphasizing early detection methods and limited treatments, while advocating for proactive health management and improved patient-provider communication.

In this episode, I’m focusing on fatty liver disease, a condition that is incredibly common and still easy to miss, especially in people living with obesity and type 2 diabetes. I use a real patient scenario from clinic to show how often this comes up in everyday primary care and why so many people are surprised to hear their liver may be at risk. I walk through the numbers and what they actually mean in real life, because fatty liver disease is not just a “benign finding” on a scan. Over time it can progress from simple fat buildup to inflammation, then fibrosis, and in some patients it advances to cirrhosis and even liver cancer. That progression is exactly why I keep coming back to early detection. Most people do not feel symptoms until late, which means waiting for symptoms is the wrong strategy. I explain the practical tools we use to catch this earlier, including a liver ultrasound and a simple scoring system called the FIB 4 index, which uses routine lab values and age to estimate the risk of fibrosis. The goal is to identify who is low risk, who needs closer monitoring, and who may need more advanced testing. I also cover treatment options. The most important treatment is improving metabolic health, especially weight loss and better control of diabetes. For some patients, there are medication options that may help when the disease has progressed to higher risk fibrosis categories, including resmetirom and semaglutide, alongside lifestyle changes. My message at the end is straightforward. Fatty liver disease is common, it can become serious, and we can do something about it when we catch it early. I want patients to feel empowered to ask about their risk and I want clinicians to make this a routine part of proactive care, because better conversations and earlier screening lead to better outcomes.

💡 Start your journey today with Maryland Primary Care & Wellness
Book your consultation: https://www.maryland-primarycare.com/

Dr. Takem and Dr. Usman Khan discuss the use of GLP-1 medications like Ozempic for obesity, emphasizing realistic weight loss expectations, the importance of lifestyle changes, and the need for credible health information.

In this episode, I’m joined by Dr. Usman Khan to talk about GLP-1 medications like Ozempic and what they can realistically do for weight loss and obesity treatment. We go straight into the concerns I hear from patients all the time, especially fears about side effects and misinformation that spreads online. Dr. Khan and I break down what outcomes actually look like, and why these medications work best when they’re part of a bigger plan that includes nutrition, habits, and movement. We also discuss how social media has shaped public perception of GLP-1s, often creating confusion and unnecessary fear. Our message is simple: use credible medical sources and talk to your physician, not influencers. We close with an important reminder: GLP-1 medications can be a powerful tool for the right person, but they’re not for everyone, and the decision should always be made with a healthcare professional who knows your medical history.

💡 Start your journey today with Maryland Primary Care & Wellness
Book your consultation: https://www.maryland-primarycare.com/

Dr. Russ and Dr. Takem discuss joint injections for arthritis, noting a 50% to 70% pain reduction and the emphasis on functional improvement. They stress patient education and thorough evaluations for effective pain management.

In this episode, Dr. Russ and I break down what joint injections can realistically do for arthritis pain, and what they cannot do. Most patients can expect about a 50% to 70% reduction in pain, but the outcome depends on the person, the joint, and what else might be contributing to the symptoms. I spend a lot of time reframing the goal, because many people come in hoping for complete relief. With arthritis, that expectation usually sets you up for disappointment. An injection can calm inflammation and reduce pain, but it does not cure the underlying wear and tear. The real win is function. Better sleep, longer walks, easier stairs, and getting back to daily life with less limitation. We also talk about why patient education matters so much. When you understand the purpose and limitations of treatment ahead of time, the experience feels clearer and the results make more sense. We discuss how we use clinical tools to measure improvement and why a meaningful change on a pain scale can translate into a big upgrade in quality of life. Finally, we cover what it means if an injection does not help the way we expected. Sometimes there is more going on than arthritis alone, and that is when we step back and evaluate more thoroughly to find the real pain drivers. The goal is always the same. A patient-centered plan that improves your function and your life, not just a number.

💡 Start your journey today with Maryland Primary Care & Wellness
Book your consultation: https://www.maryland-primarycare.com/